Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATEA PHARMACEUTICALS, INC.

(AVIR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
27.88(c) 27.72(c) 25.98(c) 27.13(c) 26.23(c) Last
1 062 988 1 163 646 1 863 522 1 842 067 3 175 905 Volume
-2.52% -0.57% -6.28% +4.43% -3.32% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 288 M - -
Net income 2021 52,3 M - -
Net cash position 2021 666 M - -
P/E ratio 2021 42,2x
Yield 2021 -
Sales 2022 2 655 M - -
Net income 2022 1 262 M - -
Net cash position 2022 1 737 M - -
P/E ratio 2022 2,03x
Yield 2022 -
Capitalization 2 171 M 2 171 M -
EV / Sales 2021 5,23x
EV / Sales 2022 0,16x
Nbr of Employees 49
Free-Float 81,5%
More Financials
Company
Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of product candidates to treat coronavirus disease (COVID-19), dengue, chronic hepatitis C (HCV), and respiratory syncytial virus (RSV).... 
More about the company
Ratings of Atea Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ATEA PHARMACEUTICALS, INC.
09/09ATEA PHARMACEUTICALS : SVB Leerink Starts Atea Pharmaceuticals at Outperform wit..
MT
09/07Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Heal..
GL
09/01Pfizer, Merck launch new trials of oral COVID-19 drugs
RE
09/01Pfizer starts dosing patients in oral COVID-19 drug trial
RE
08/24Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752's Pote..
GL
08/24Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Pote..
CI
08/18ATEA PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Atea Pharmaceutica..
MT
08/12ATEA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Conditi..
AQ
08/12ATEA PHARMACEUTICALS : Swings to Q2 Profit; Shares Rise After Hours
MT
08/12ATEA PHARMACEUTICALS : Second Quarter 2021 Financial Results Conference Call Pre..
PU
08/12ATEA PHARMACEUTICALS : Provides Clinical and Corporate Update and Reports Second..
PU
08/12ATEA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fina..
AQ
08/12ATEA PHARMACEUTICALS : Provides Clinical and Corporate Update and Reports Second..
AQ
08/12Atea Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results fo..
CI
08/05Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call..
GL
More news
News in other languages on ATEA PHARMACEUTICALS, INC.
06/30ROCHE : résultats positifs sur un antiviral contre le Covid
More news
Analyst Recommendations on ATEA PHARMACEUTICALS, INC.
More recommendations
Chart ATEA PHARMACEUTICALS, INC.
Duration : Period :
Atea Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATEA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 26,23 $
Average target price 65,00 $
Spread / Average Target 148%
EPS Revisions
Managers and Directors
Jean-Pierre Sommadossi Chairman, President & Chief Executive Officer
Andrea J. Corcoran Chief Financial Officer, Secretary & EVP-Legal
Maria Arantxa Horga Chief Medical Officer
Keith Pietropaolo Senior Vice President-Clinical Operations
Claudio Avila Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ATEA PHARMACEUTICALS, INC.-37.22%2 171
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850